Content about Pfizer

July 23, 2012

A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

NEW YORK — A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

The drug maker announced Monday the results of study A0081104 of Lyrica (pregabalin), which compared the drug with placebo in healthy males to assess its effects on sperm production. The phase-4 study was required by the Food and Drug Administration.

July 18, 2012

Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic version of a popular cholesterol drug.

The company announced Wednesday the launch of atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths.

The drug is a generic version of Pfizer's Lipitor, which had sales of slightly more than $8 billion during the 12-month period ended in March, according to IMS Health.

July 5, 2012

The Food and Drug Administration has approved Lupin Pharmaceuticals' generic version of a drug used to treat pain and seizure disorders.

BALTIMORE — The Food and Drug Administration has approved Lupin Pharmaceuticals' generic version of a drug used to treat pain and seizure disorders.

Lupin announced the approval of pregabalin capsules in the 25-mg, 50-mg, 75-mg, 100-mg, 150-mg, 200-mg, 225-mg and 300-mg strengths. The drug is used to treat fibromyalgia, partial-onset seizures in adults, neuropathic pain associated with diabetic peripheral neuropathy and post-herpetic neuralgia.

June 28, 2012

Mylan is challenging the patent protection on a Pfizer drug for treating depression, following an announcement of a similar challenge by Watson made earlier this week.

PITTSBURGH — Mylan is challenging the patent protection on a Pfizer drug for treating depression, following an announcement of a similar challenge by Watson made earlier this week.

Mylan said it had filed for Food and Drug Administration approval of a generic version of Pristiq (desvenlafaxine succinate) extended-release tablets in the 50-mg and 100-mg strengths.

June 26, 2012

Generic drug maker Watson Pharmaceuticals is challenging the patent protection on an antidepressant made by Pfizer, the company said.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals is challenging the patent protection on an antidepressant made by Pfizer, the company said.

Watson filed a regulatory approval application with the Food and Drug Administration for desvenlafaxine succinate extended-release tablets in the 50-mg and 100-mg strengths. The drug is a generic version of Pfizer's Pristiq.

June 21, 2012

The Food and Drug Administration has approved a new indication for a Pfizer drug.

NEW YORK — The Food and Drug Administration has approved a new indication for a Pfizer drug.

Lyrica (pregabalin) capsules CV now can be used for the management of neuropathic pain associated with spinal cord injury. The drug received a priority review designation for this new indication as more than 100,000 patients — approximately 40% of the 270,000 patients with spinal cord injury in the United States — suffer from this chronic, complex pain condition.

June 19, 2012

The Food and Drug Administration has declined to approve a drug designed to treat a rare, progressive and fatal neurodegenerative disease.

NEW YORK — The Food and Drug Administration has declined to approve a drug designed to treat a rare, progressive and fatal neurodegenerative disease.

The FDA issued a complete response letter to Pfizer pertaining to the company's new drug application for tafamidis meglumine, requesting the completion of a second efficacy study to establish substantial evidence of effectiveness prior to an approval. The agency also has asked for additional information on the data within the current tafamidis NDA.

June 19, 2012

Pfizer announced the results of its late-stage clinical trial of Xalkori (crizotinib).

NEW YORK — Pfizer announced the results of its late-stage clinical trial of Xalkori (crizotinib).

The drug maker confirmed that its Profile 1007 study met its primary endpoint, demonstrating that the drug significantly improved progression-free survival in previously treated patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, compared with those treated with pemetrexed or docetaxel. The study also marked the first randomized phase-3 study in ALK-positive advanced NSCLC patients, Pfizer said.

June 18, 2012

Greenstone, the generic pharmaceutical subsidiary of Pfizer, has launched olanzapine tablets.

PEAPACK, N.J. — Greenstone, the generic pharmaceutical subsidiary of Pfizer, has launched olanzapine tablets.

The drug, which is a generic version of Zyprexa — an Eli Lilly drug used to treat psychiatric disorders — in the 2.5-mg, 5-mg, 7.5-mg, 10-mg, 15-mg and 20-mg strengths.

Generic and branded versions of the drug had sales of about $3.28 billion during the 12-month period ended in January, according to IMS Health.

June 7, 2012

The Food and Drug Administration has approved a drug made by GlaxoSmithKline and XenoPort for treating pain associated with shingles.

NEW YORK — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and XenoPort for treating pain associated with shingles.

The drug makers announced Thursday the approval of Horizant (gabapentin enacarbil) extended-release tablets for managing post-herpetic neuralgia. The drug already had FDA approval for treating restless legs syndrome. The approval entitles XenoPort to a $10 million milestone payment from GSK, according to a collaborative agreement between the two companies.

June 1, 2012

WebMD has tapped Pfizer's group president of animal health, consumer health care and corporate strategy to serve as its new chief executive.

NEW YORK — WebMD has tapped Pfizer's group president of animal health, consumer health care and corporate strategy to serve as its new chief executive.

Cavan Redmond was appointed CEO of WebMD, as well as a member of the company's board of directors on Thursday. He brings to his new role more than 20 years of healthcare experience, encompassing a broad range of global healthcare businesses, including biotechnology, pharmaceuticals, consumer health care and infant nutritionals.

May 29, 2012

An experimental drug made by Pfizer for a rare and fatal neurodegenerative disease got a favorable vote from a Food and Drug Administration expert panel.

NEW YORK — An experimental drug made by Pfizer for a rare and fatal neurodegenerative disease got a favorable vote from a Food and Drug Administration expert panel.

The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 13-4 that the drug tafamidis meglumine would provide certain clinical benefits to patients with transthyretin familial amyloid polyneuropathy, or TTR-FAP, a hereditary disease that affects about 8,000 people worldwide. The FDA is not required to follow the recommendations of FDA advisory committees, but usually does.

May 29, 2012

Mylan on Tuesday announced that its subsidiary has received final approval from the Food and Drug Administration for its abbreviated new drug application for atorvastatin calcium tablets, a generic version of Pfizer's Lipitor.

PITTSBURGH — Mylan on Tuesday announced that its subsidiary has received final approval from the Food and Drug Administration for its abbreviated new drug application for atorvastatin calcium tablets, a generic version of Pfizer's Lipitor.

The drug maker said Mylan Labs (formerly Matrix Labs) received the go-ahead to market the drug in the 10-mg, 20-mg, 40-mg and 80-mg strengths. Lipitor had U.S. sales of $8.1 billion for the 12 months ended in March, according to IMS Health.

May 23, 2012

Pfizer has named one of its executives to a new position.

NEW YORK — Pfizer has named one of its executives to a new position.

Olivier Brandicourt — Pfizer's president and general manager of the primary care business unit and a member of the Pfizer executive leadership team — has been appointed president and general manager of the company's emerging markets and established business products business units, effective June 1. He succeeds David Simmons, who is leaving Pfizer to become the chairman and CEO of Pharmaceutical Product Development.

May 23, 2012

Pfizer has partnered with EatingWell magazine to launch the drug maker's Lipitor For You "Recipes 2 Go" mobile application.

NEW YORK — Pfizer has partnered with EatingWell magazine to launch the drug maker's Lipitor For You "Recipes 2 Go" mobile application.

May 17, 2012

The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved generic versions of one of the country's top-selling drugs made by eight different companies, the agency said Thursday.

May 17, 2012

Sagent Pharmaceuticals has launched a generic version of a chemotherapy drug, the company said Thursday.

SCHAUMBURG, Ill. — Sagent Pharmaceuticals has launched a generic version of a chemotherapy drug, the company said Thursday.

Sagent announced the launch of irinotecan injection, a generic version of Pfizer's Camptosar, in latex-free, preservative-free, single-dose vials.

Various versions of the drug had sales of about $28 million during the 12-month period ended in March, according to IMS Health.

May 16, 2012

An experimental kidney cancer drug made by Pfizer didn't extend the time in which patients survived without their disease worsening when compared with a competing drug, according to results of a late-stage clinical trial released Wednesday.

NEW YORK — An experimental kidney cancer drug made by Pfizer didn't extend the time in which patients survived without their disease worsening when compared with a competing drug, according to results of a late-stage clinical trial released Wednesday.

May 15, 2012

Pfizer apparently is relenting on its attempt to drive sales of its top cholesterol drug as several new generic versions look set to enter the market, according to published reports.

NEW YORK — Pfizer apparently is relenting on its attempt to drive sales of its top cholesterol drug as several new generic versions look set to enter the market, according to published reports.

The Associated Press reported that Pfizer was "quietly" giving up on the drug Lipitor (atorvastatin) after an $87 million campaign to continue marketing the drug despite generic competition.

May 10, 2012

A Food and Drug Administration expert panel has recommended approval for a drug made by Pfizer for treating rheumatoid arthritis.

NEW YORK — A Food and Drug Administration expert panel has recommended approval for a drug made by Pfizer for treating rheumatoid arthritis.

May 4, 2012

A 30% rise in attendance at the Armada Specialty Pharmacy Summit is nothing to brush off — it's as clear an indication as any that specialty pharmacy is growing and probably poised for more growth in the near future, thanks in particular to the aging population and consequential rise in the number of people living with difficult-to-treat medical conditions.

WHAT IT MEANS AND WHY IT'S IMPORTANT — A 30% rise in attendance at the Armada Specialty Pharmacy Summit is nothing to brush off — it's as clear an indication as any that specialty pharmacy is growing and probably poised for more growth in the near future, thanks in particular to the aging population and consequential rise in the number of people living with difficult-to-treat medical conditions.

May 3, 2012

Drug makers could strike big with new treatments for rare diseases, according to a new report by a market research firm.

NEW YORK — Drug makers could strike big with new treatments for rare diseases, according to a new report by a market research firm.

May 2, 2012

The Food and Drug Administration has approved a new treatment for a rare genetic disorder that affects 10,000 people worldwide.

NEW YORK — The Food and Drug Administration has approved a new treatment for a rare genetic disorder that affects 10,000 people worldwide.

Pfizer and Protalix BioTherapeutics announced Wednesday the approval of Elelyso (taliglucerase alfa), an enzyme-replacement therapy for the long-term treatment of Type 1 Gaucher disease.

April 27, 2012

Two companies have settled with Teva over the latter's efforts to launch a generic version of an emergency treatment for allergic reactions.

NEW YORK — Two companies have settled with Teva over the latter's efforts to launch a generic version of an emergency treatment for allergic reactions.

Under the agreement, involving Mylan and Pfizer's Meridian Medical Technologies subsidiary, Teva will be allowed to launch a generic version of EpiPen (epinephrine) auto-injector in June 2015, assuming it wins approval from the Food and Drug Administration. Mylan Specialty markets the EpiPen, which Meridian manufactures.

April 23, 2012

Pfizer is selling its nutrition business to Nestle for $11.85 billion, Pfizer said Monday.

NEW YORK — Pfizer is selling its nutrition business to Nestlé for $11.85 billion, Pfizer said Monday.

Pfizer Nutrition, which had sales of about $2.1 billion in 2011, manufactures and markets nutrition products for children, including baby and toddler formulas, follow-on formulas and maternal and adult nutrition products.